Benefits of statin therapy identified

NewsGuard 100/100 Score

The greater the reduction in LDL (lower-density lipoprotein) cholesterol achieved by statin therapy the greater the reduction in incidence of major coronary events, coronary revascularisation and stroke, concludes a meta-analysis published online today by The Lancet. Goals for statin treatment should aim to achieve substantial absolute reductions in LDL cholesterol, state the authors.

Results of previous randomised trials have shown that statins can significantly reduce the incidence of coronary heart disease in a wide range of individuals. But uncertainties about their effects on mortality and major illness have persisted and some trials had suggested that statins increase the risk of particular cancers. In the first meta-analysis of its kind, Colin Baigent and colleagues from the Clinical Trial Service Unit (CTSU) at Oxford University and Anthony Keech and colleagues from the NHMRC Clinical Trials Centre (CTC) in Sydney, combined data from 14 randomised trials of statins involving over 90 000 patients.

The investigators found that statin therapy could reduce the 5-year incidence of major coronary events and stroke by about one fifth per mmol/L reduction in LDL cholesterol, irrespective of a person’s pre-treatment cholesterol level or other characteristics. Dr. Baigent states: “The absolute benefits increased with continuing treatment and treatment produced a clear reduction in all-cause mortality. There was no evidence that lowering LDL cholesterol by 1 mmol/L with 5 years of statin therapy increased the risk of any specific cancer.”

Professor Keech states: “Full compliance with available statin regimens can reduce LDL cholesterol by at least 1·5 mmol/L in many circumstances, and hence might be expected to reduce the incidence of major vascular events by about one third. Ensuring that patients at high 5-year risk of any type of occlusive major vascular event achieve and maintain a substantial reduction in LDL cholesterol would result in major clinical and public-health benefits."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients